论文部分内容阅读
目的:探讨同步放化疗联合射频消融术治疗非小细胞肺癌的临床疗效。方法:将40例非小细胞肺癌患者随机分为放化疗联合射频消融术(综合组,n=19)和单纯放化疗(对照组,n=21)。化疗采用常规EP方案,放疗为适形放疗。分别于治疗完成后3、6个月和1、2、3年复查,从KPS、肿瘤大小、生存率对患者进行临床评价,研究综合治疗的临床疗效。结果:综合治疗的KPS评分及肿瘤体积减小明显高于对照组,且差异有统计学意义,P<0.05。有效率(CR+PR)综合组为78.9%,而对照组为42.9%。综合组6个月、1、2和3年生存率分别约为100.0%(19/19)、89.4%(17/19)、73.6%(14/19)和57.9%(11/19);对照组分别为100%(21/21)、76.2%(16/21)、47.6%(10/21)和28.6%(6/21),3年生存率差异有统计学意义,P=0.03。结论:放化疗联合射频消融治疗非小细胞肺癌能显著增强疗效,提高患者生存率,是目前较理想、值得临床广泛推广的一种综合治疗方法。
Objective: To investigate the clinical efficacy of simultaneous radiotherapy and radiofrequency ablation for non-small cell lung cancer. Methods: Forty patients with NSCLC were randomly divided into radiotherapy and chemotherapy plus radiofrequency ablation (comprehensive group, n=19) and radiotherapy and chemotherapy alone (control group, n=21). Chemotherapy was performed using conventional EP regimens and radiotherapy was conformal radiotherapy. Were reviewed at 3, 6 months and 1, 2 and 3 years after completion of treatment, and clinical evaluation was performed on the patients from KPS, tumor size, and survival rate to study the clinical efficacy of comprehensive treatment. Results: The KPS score and the tumor volume decreased significantly in the comprehensive treatment compared with the control group, and the difference was statistically significant (P<0.05). The effective (CR+PR) comprehensive group was 78.9%, while the control group was 42.9%. The 6-month, 1-, 2-, and 3-year survival rates of the comprehensive group were approximately 100.0% (19/19), 89.4% (17/19), 73.6% (14/19), and 57.9% (11/19) respectively; The group was 100% (21/21), 76.2% (16/21), 47.6% (10/21), and 28.6% (6/21). The 3-year survival rate was statistically significant, P = 0.03. Conclusion: Radiotherapy combined with radiofrequency ablation for non-small cell lung cancer can significantly enhance the curative effect and improve the survival rate of patients. It is a comprehensive treatment method that is currently ideal and worthy of widespread clinical application.